DC-CIK Cells Immunotherapy Study On The Immune Function Of Patients With Bile Duct Carcinoma After Surgery

Objective：Development is more than a factor of tumor development participation,multi-step process, in the process factors play an important role in the body’s immunefunction, therefore, in the process of diagnosis and treatment of tumor diseases, in additionto the traditional surgery and radiation and chemotherapy, but also emphasis on correctingimmune defects existing in the body. Under the background of the study, tumor biologicaltherapy concept arises at the historic moment, the fourth mode for tumor therapy. Whichbased on the DC-CIK cells of antitumor immune therapy, become a research hotspot athome and abroad.Dendritic cells (Dendritic cells, DC) is a powerful professional antigenpresenting cells (antigen presenting cell, APC), can be efficiently mediated for specificantigen specific immune response. Cytokine induced killer cells (cytokine induced killercells, CIK) is a new type of high efficient immune effector cells, the MHC restricted killtumor activity, high proliferation speed, killing activity. Will be able to identify antigen andactivate the immune system of DC and highly effective kill tumor activity of CIK jointtraining for the treatment of tumors, for tumor biological therapy has opened up a newperspective.This experiment will bile duct carcinoma antigen load DC and CIK trained, and isapplied to DC-CIK20cases of postoperative patients with advanced cholangiocarcinoma,observed in patients with recent clinical curative effect and the change of immune function,provide the basis for clinical biological treatment.Methods：Selected from September2010to October2012Da Vinci robot aided by40patients with cholangiocarcinoma local excision or radical surgery, can be divided intoDC-CIK cell treatment group (n=20) and conventional treatment group (n=20). In20cases of treatment group patients peripheral blood DC-CIK cells, in vitro induction ofDC-CIK cells, the back loss to patients, compared with its back to lose before and4weeks after back to lose immune function, serum levels of CA19-9, IL-6, IFN–γ value, usestatistical methods to analyze DC-CIK cells between treatment group and routine treatmentgroup each index changes in the presence of differences. Observe two groups improved therecent curative effect, clinical benefit response, tumor markers, and the quality of life scoreKarnofsky (KPS) and without serious complications.Results：1. DC-CIK cell treatment group after doping, peripheral blood CD3+CD56+CD16+, CD8+CD38+, CD8+DR, CD3+CD8+and CD3+cells percentage wereincreased (P <0.05), Il-6in serum values decreased (P <0.05), IFN–γ value increases (P<0.05);2.6patients serum CA19-9value decreased significantly;3.13patients KPSscore increased significantly;4.20cases of treated patients, except3cases did not seeobvious change, the rest are in different degrees, appetite and energy improvementcancerous pain relief and weight gain;5.3cases with transient fever after doping, in38℃or so commonly, for3to5h, no allergy, shock and other adverse reactions, no bonemarrow suppression, liver and kidney damage, etc.Conclusion：Postoperative patients with advanced cholangiocarcinoma DC-CIK, afterback to lose most of the patients usually get improved significantly, the immune functionhave different degrees of improvement, effectively control tumors, significantly improvethe quality of life, and no obvious adverse reaction, has higher security.